[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354131-105":59,"doc-detail-354131-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","human-ipsc-derived-and-conventional-cancer-models-in-precision-oncology-advancing-patient-specific-therapies-from-bench-to-bedside","Human iPSC-derived and conventional cancer models in precision oncology - advancing patient-specific therapies from bench to bedside","","Targeted cancer therapies, including monoclonal antibodies and lipid nanomedicines, improve specificity and extend survival, yet remain constrained by tumor heterogeneity, adaptive resistance, and complex microenvironmental effects. Conventional preclinical systems such as cell lines, patient-derived xenografts, and organoids clarify mechanisms but often fail to forecast long-term, patient-specific outcomes, slowing precision oncology translation. This review contrasts conventional in vitro approaches with hiPSC-derived cancer models, highlighting renewable patient-tailored platforms and integration with lineage tracing, multi-omics, and organ-on-chip technologies. It evaluates hiPSC-derived models’ added value, limitations, and future directions including epigenetic mapping, nanoscale testing, and AI-driven analytics.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/human-ipsc-derived-and-conventional-cancer-models-in-precision-oncology-advancing-patient-specific-therapies-from-bench-to-bedside/354131/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/human-ipsc-derived-and-conventional-cancer-models-in-precision-oncology-advancing-patient-specific-therapies-from-bench-to-bedside/354131.png","ImageObject",300,407,{"name":92,"@type":93},"Putri","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why do targeted cancer therapies still face limitations in precision oncology?","Question",{"text":112,"@type":113},"Because tumor heterogeneity, adaptive resistance, and complex microenvironmental factors can restrict therapeutic effectiveness, even for therapies that increase specificity and survival.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What shortcomings limit conventional preclinical models for patient-specific predictions?",{"text":117,"@type":113},"Cancer cell lines often miss intratumoral heterogeneity and can accumulate genetic drift, while xenografts are expensive and species-dependent, and organoids may not fully model tumor–environment interactions or scale well.",{"name":119,"@type":110,"acceptedAnswer":120},"How do hiPSC-derived cancer models aim to bridge translational gaps?",{"text":121,"@type":113},"They provide renewable, patient-specific platforms that leverage oncogenic mutations and can be combined with lineage tracing, multi-omics, and organ-on-chip approaches to better connect genotypes with responses.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354131,1790484346,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085571259,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Pant etal. Journal of Experimental & Clinical Cancer Research (2026) 45:114 [https://doi.org/10.1186/s13046-026-03694-7](https://doi.org/10.1186/s13046-026-03694-7)  \nJournal of Experimental & Clinical Cancer Research  \nREVIEW Open Access  \nHuman iPSC-derived and conventional cancer   models in precision oncology: advancing patient-specific therapies from bench to bedside  \nTarun Pant1,2*, Raman Gulab Brajesh3, Billy W. Day4, Abhishikt David Solomon5, Matea Juric6, Jacek Zielonka6 and Xiaowen Bai7*  \nAbstract  \nTargeted cancer therapies, including monoclonal antibodies and lipid nanomedicines, continue to enhance cancer treatment by increasing specificity and prolonging survival. Their therapeutic potential remains, however, limited by tumor heterogeneity, adaptive resistance, and complex microenvironmental factors. Conventional preclinical models, including cancer cell lines, patient-derived xenografts, and organoids, have helped elucidate mechanisms but fail to accurately predict long-term, patient-specific outcomes. This is a methodological gap that still hinders precision oncology, where the main goal is to tailor therapies to individual patients. In this review, we describe conventional in vitro models while focusing on recent developments in the generation and use of human-induced pluripotent stem cell (hiPSC)-derived cancer models. These systems offer distinct opportunities to bridge translational gaps by leveraging oncogenic mutations, providing renewable patient-specific platforms, and combining with lineage tracing, multi-omics, and organ-on-chip technologies. We also evaluate the role of hiPSCderived models in complementing the existing platforms and discuss current limitations and future development, such as epigenetic mapping, nanoscale testing, and AI-driven analytics, thereby making hiPSC-based cancer models a new, highly promising tool for precision oncology.  \nKeywords Human induced pluripotent stem cells (hiPSCs), Cancer modeling, Precision oncology, Organoid, AI-derived predictive analytics, Therapeutic resistance, Patient-specific drug response  \n*Correspondence:  \nTarun Pant[tpant@mcw.edu](tpant@mcw.edu)[ ](tpant@mcw.edu)Xiaowen Bai [Xiaowen.Bai@osumc.edu](Xiaowen.Bai@osumc.edu)  \n1Department of Surgery, Division of Pediatric Surgery, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA 2Children’s Research Institute, Children’s Wisconsin, Milwaukee, WI 53226, USA  \n3Department of Biomedical Engineering and Bioinformatics, Swami Vivekanand Technical University, Durg 491107, India 4ReNeuroGen LLC, Milwaukee, WI 53122, USA  \n5Adams School of Dentistry, Oral and Craniofacial Biomedicine, University of North Carolina, Chapel Hill, NC 27599, USA  \n6Department of Biophysics, Medical College of Wisconsin, 8701  \nWatertown Plank Road, Milwaukee, WI 53226, USA  \n7Department of Anesthesiology, Wexner Medical Center, The Ohio State University, 420 West 12Th Avenue, Columbus, OH 43210, USA  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The)[. The](http://creativecommons.org/licenses/by/4.0/. The)[ ](http://creativecommons.org/licens","cbCairJRU09Jpmy4","https://ap.wps.com/l/cbCairJRU09Jpmy4","pdf",6464996,23,"English","# Abstract\n# Introduction\n## Targeted therapies and precision oncology barriers\n## Limitations of conventional preclinical models\n## Emerging role of patient-derived organoids and need for new platforms\n## Promise of hiPSCs in cancer modeling","[{\"question\":\"Why do targeted cancer therapies still face limitations in precision oncology?\",\"answer\":\"Because tumor heterogeneity, adaptive resistance, and complex microenvironmental factors can restrict therapeutic effectiveness, even for therapies that increase specificity and survival.\"},{\"question\":\"What shortcomings limit conventional preclinical models for patient-specific predictions?\",\"answer\":\"Cancer cell lines often miss intratumoral heterogeneity and can accumulate genetic drift, while xenografts are expensive and species-dependent, and organoids may not fully model tumor–environment interactions or scale well.\"},{\"question\":\"How do hiPSC-derived cancer models aim to bridge translational gaps?\",\"answer\":\"They provide renewable, patient-specific platforms that leverage oncogenic mutations and can be combined with lineage tracing, multi-omics, and organ-on-chip approaches to better connect genotypes with responses.\"}]","Human iPSC-derived and conventional cancer models in precision oncology - advancing patient-specific therapies from bench to bedside | PDF",1790109175,58,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bf9141d1d0c276a88e41d09d8aa1b698.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff7fa1029f510a90f65bfee7a4e2e7bf.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12b2b64d0ca691e76e917185b6948f28.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46471dbf3d22518ddaab29d6a74ba452.webp",980,1306]